Business Description
Strides Pharma Science Ltd
ISIN : INE939A01011
Compare
Compare
Traded in other countries / regions
STAR.India IPO Date
2000-02-02Description
Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market planĀ focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth planĀ for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.12 | |||||
| Equity-to-Asset | 0.36 | |||||
| Debt-to-Equity | 1.18 | |||||
| Debt-to-EBITDA | 5.54 | |||||
| Interest Coverage | 1.96 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.85 | |||||
| Beneish M-Score | -3.14 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.6 | |||||
| 3-Year EBITDA Growth Rate | -15.5 | |||||
| 3-Year FCF Growth Rate | 46.1 | |||||
| 3-Year Book Growth Rate | -9.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 13.49 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.27 | |||||
| 9-Day RSI | 58.76 | |||||
| 14-Day RSI | 59.93 | |||||
| 6-1 Month Momentum % | 70.77 | |||||
| 12-1 Month Momentum % | 163.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.03 | |||||
| Quick Ratio | 0.64 | |||||
| Cash Ratio | 0.1 | |||||
| Days Inventory | 235.66 | |||||
| Days Sales Outstanding | 110.39 | |||||
| Days Payable | 191.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.18 | |||||
| Dividend Payout Ratio | 0.13 | |||||
| 3-Year Dividend Growth Rate | -9.1 | |||||
| Forward Dividend Yield % | 0.18 | |||||
| 5-Year Yield-on-Cost % | 0.18 | |||||
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | 3.4 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 56.51 | |||||
| Operating Margin % | 13.42 | |||||
| Net Margin % | 0.17 | |||||
| FCF Margin % | 14.4 | |||||
| ROE % | 0.31 | |||||
| ROA % | 0.11 | |||||
| ROIC % | 23.76 | |||||
| 3-Year ROIIC % | -27.32 | |||||
| ROC (Joel Greenblatt) % | 9.49 | |||||
| ROCE % | 7.48 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 2639.63 | |||||
| Forward PE Ratio | 27.75 | |||||
| PE Ratio without NRI | 124.16 | |||||
| Shiller PE Ratio | 71.03 | |||||
| PS Ratio | 3.17 | |||||
| PB Ratio | 6.04 | |||||
| Price-to-Tangible-Book | 12.03 | |||||
| Price-to-Free-Cash-Flow | 21.87 | |||||
| Price-to-Operating-Cash-Flow | 18.18 | |||||
| EV-to-EBIT | 61.7 | |||||
| EV-to-EBITDA | 33.22 | |||||
| EV-to-Revenue | 3.73 | |||||
| EV-to-FCF | 26.06 | |||||
| Price-to-Projected-FCF | 8.34 | |||||
| Price-to-Median-PS-Value | 1.62 | |||||
| Price-to-Graham-Number | 15.8 | |||||
| Earnings Yield (Greenblatt) % | 1.62 | |||||
| FCF Yield % | 4.53 | |||||
| Forward Rate of Return (Yacktman) % | -7.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Ā
Total Annual Return % Ā
Strides Pharma Science Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ā¹) | 40,485.32 | ||
| EPS (TTM) (ā¹) | 0.53 | ||
| Beta | 1.62 | ||
| Volatility % | 40.01 | ||
| 14-Day RSI | 59.93 | ||
| 14-Day ATR (ā¹) | 58.221825 | ||
| 20-Day SMA (ā¹) | 1360.9825 | ||
| 12-1 Month Momentum % | 163.74 | ||
| 52-Week Range (ā¹) | 467 - 1445 | ||
| Shares Outstanding (Mil) | 91.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Strides Pharma Science Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Strides Pharma Science Ltd Stock Events
| Event | Date | Price(ā¹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Strides Pharma Science Ltd Frequently Asked Questions
What is Strides Pharma Science Ltd(NSE:STAR)'s stock price today?
The current price of NSE:STAR is ā¹1399.00. The 52 week high of NSE:STAR is ā¹1445.00 and 52 week low is ā¹467.00.
When is next earnings date of Strides Pharma Science Ltd(NSE:STAR)?
The next earnings date of Strides Pharma Science Ltd(NSE:STAR) is .
Does Strides Pharma Science Ltd(NSE:STAR) pay dividends? If so, how much?
TheĀ Dividend Yield % Ā of Strides Pharma Science Ltd(NSE:STAR) is 0.18% (As of Today), HighestĀ Dividend Payout RatioĀ of Strides Pharma Science Ltd(NSE:STAR) was 4.54. The lowest was 0.09. And the median was 0.47. The Ā Forward Dividend Yield % of Strides Pharma Science Ltd(NSE:STAR) is 0.18%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers